董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Meenu Chhabra | 女 | President, Chief Executive Officer and Director | 43 | 158.57万美元 | 未持股 | 2016-04-20 |
| Jeffery W. Kelly | 男 | Director | 55 | 6.60万美元 | 未持股 | 2016-04-20 |
| Conor M. Walshe | 男 | Director | 42 | 未披露 | 未持股 | 2016-04-20 |
| Helen Boudreau | 女 | Director | 50 | 未披露 | 未持股 | 2016-04-20 |
| Franklin M. Berger | 男 | Director | 66 | 未披露 | 未持股 | 2016-04-20 |
| Christopher K. Mirabelli | 男 | Chairman of the Board of Directors | 61 | 未披露 | 未持股 | 2016-04-20 |
| M. James Barrett | 男 | Director | 73 | 未披露 | 未持股 | 2016-04-20 |
| Christopher T. Walsh | 男 | Director | 72 | 1.60万美元 | 未持股 | 2016-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Meenu Chhabra | 女 | President, Chief Executive Officer and Director | 43 | 158.57万美元 | 未持股 | 2016-04-20 |
| Lance Thibault | 男 | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | 49 | 未披露 | 未持股 | 2016-04-20 |
| Po Shun Lee | 男 | Executive Vice President and Chief Medical Officer | 46 | 70.33万美元 | 未持股 | 2016-04-20 |
| Benito Munoz | 男 | Senior Vice President, Drug Discovery | 54 | 未披露 | 未持股 | 2016-04-20 |
| Janet L. Smart | 女 | Vice President, Intellectual Property and Legal Affairs | 59 | 31.94万美元 | 未持股 | 2016-04-20 |
董事简历
中英对照 | 中文 | 英文- Meenu Chhabra
-
Meenu Chhabra，自2014年5月起担任总裁、首席执行官和董事会成员。2007年8月-2014年5月她成为 Allozyne股份有限公司（ Allozyne, Inc.，一家生物制药公司）的总裁和首席执行官。2006年12月-2007年8月她担任Novartis AG NYSE： NVS。 的诺华（Novartis）制药部门的商务拓展和认证副总裁。2003年7月-2006年11月她在BioXell SpA（从F. Hoffmann-LaRoche Ltd.的米兰研究所（Milan Research Institute意大利（Italy））分离出来的公司）担任首席商务官，负责公司拓展和财务活动。Chhabra女士也在Fresenius Kabi AG、Warner-Lambert Company有限责任公司（Warner-Lambert Company, LLC）和Bristol-Myers Squibb公司（Bristol-Myers Squibb Company ,NYSE： BMY）担任管理职位。她获得约克大学（York University）工商管理硕士学位和多伦多大学（University of Toronto）学士学位。
Meenu Chhabra has been serving as our President and Chief Executive Officer and a member of our Board of Directors since May 2014. From August 2007 to May 2014 Ms. Chhabra was President and Chief Executive Officer at Allozyne, Inc., a biopharmaceutical company. From December 2006 to August 2007 she served as Vice President of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis AG NYSE: NVS. From July 2003 to November 2006 she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy), where she led corporate development and financing activities. Ms. Chhabra has also held management positions with Fresenius Kabi AG, Warner-Lambert Company, LLC, and Bristol-Myers Squibb Company (NYSE: BMY). She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto. - Meenu Chhabra，自2014年5月起担任总裁、首席执行官和董事会成员。2007年8月-2014年5月她成为 Allozyne股份有限公司（ Allozyne, Inc.，一家生物制药公司）的总裁和首席执行官。2006年12月-2007年8月她担任Novartis AG NYSE： NVS。 的诺华（Novartis）制药部门的商务拓展和认证副总裁。2003年7月-2006年11月她在BioXell SpA（从F. Hoffmann-LaRoche Ltd.的米兰研究所（Milan Research Institute意大利（Italy））分离出来的公司）担任首席商务官，负责公司拓展和财务活动。Chhabra女士也在Fresenius Kabi AG、Warner-Lambert Company有限责任公司（Warner-Lambert Company, LLC）和Bristol-Myers Squibb公司（Bristol-Myers Squibb Company ,NYSE： BMY）担任管理职位。她获得约克大学（York University）工商管理硕士学位和多伦多大学（University of Toronto）学士学位。
- Meenu Chhabra has been serving as our President and Chief Executive Officer and a member of our Board of Directors since May 2014. From August 2007 to May 2014 Ms. Chhabra was President and Chief Executive Officer at Allozyne, Inc., a biopharmaceutical company. From December 2006 to August 2007 she served as Vice President of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis AG NYSE: NVS. From July 2003 to November 2006 she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy), where she led corporate development and financing activities. Ms. Chhabra has also held management positions with Fresenius Kabi AG, Warner-Lambert Company, LLC, and Bristol-Myers Squibb Company (NYSE: BMY). She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto.
- Jeffery W. Kelly
-
Jeffery W. Kelly，是公司的联合创始人，自2006年12月公司成立起就在公司董事会工作。2008年9月起他担任位于加利福尼亚拉荷亚（La Jolla, California）的斯克里普斯研究所（The Scripps Research Institute）的Skaggs化学生物学研究所（Skaggs Institute of Chemical Biology ）的Molecular and Experimental Medicine 的董事长和Lita Annenberg Hazen化学教授。2000年8月-2008年12月他担任斯克里普斯研究所（The Scripps Research Institute）的研究生院长；2000年7月-2006年12月他也担任教务处的副主任。Kelly博士也联合创立了FoldRx Pharmaceuticals股份有限公司（FoldRx Pharmaceuticals, Inc. ）和Misfolding Diagnostics 股份有限公司（Misfolding Diagnostics Inc.）。他拥有北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）有机化学博士学位。
Jeffery W. Kelly a co-founder of our company, has served on our Board of Directors since December 2006 when our company was founded. Since September 2008 he has been serving as the Chairman of Molecular and Experimental Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. From August 2000 to December 2008 he served as Dean of Graduate Studies at The Scripps Research Institute, and from July 2000 to December 2006 he also served as Vice President of Academic Affairs. Dr. Kelly also co-founded FoldRx Pharmaceuticals, Inc. and Misfolding Diagnostics Inc. He received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. - Jeffery W. Kelly，是公司的联合创始人，自2006年12月公司成立起就在公司董事会工作。2008年9月起他担任位于加利福尼亚拉荷亚（La Jolla, California）的斯克里普斯研究所（The Scripps Research Institute）的Skaggs化学生物学研究所（Skaggs Institute of Chemical Biology ）的Molecular and Experimental Medicine 的董事长和Lita Annenberg Hazen化学教授。2000年8月-2008年12月他担任斯克里普斯研究所（The Scripps Research Institute）的研究生院长；2000年7月-2006年12月他也担任教务处的副主任。Kelly博士也联合创立了FoldRx Pharmaceuticals股份有限公司（FoldRx Pharmaceuticals, Inc. ）和Misfolding Diagnostics 股份有限公司（Misfolding Diagnostics Inc.）。他拥有北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）有机化学博士学位。
- Jeffery W. Kelly a co-founder of our company, has served on our Board of Directors since December 2006 when our company was founded. Since September 2008 he has been serving as the Chairman of Molecular and Experimental Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. From August 2000 to December 2008 he served as Dean of Graduate Studies at The Scripps Research Institute, and from July 2000 to December 2006 he also served as Vice President of Academic Affairs. Dr. Kelly also co-founded FoldRx Pharmaceuticals, Inc. and Misfolding Diagnostics Inc. He received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill.
- Conor M. Walshe
-
Conor M. Walshe ，2014年12月起在本董事会任职。在Perrigo担任几个职位，包括商务运营副总裁和独立公司发展负责人。在加入Perrigo之前，他担任Elan Pharmaceuticals股份有限公司（Elan Pharmaceuticals, Inc.）的商务运营的高级总监和财务高级总监；Alltracel Pharmaceuticals plc的 Alltracel Healthcare Services Limited负责人； ICON plc NASDAQ： ICLR的财务总监和KPMG股份有限公司（KPMG, Inc.）的审计师。他也在NewBridge Pharmaceuticals FZ 有限责任公司（NewBridge Pharmaceuticals FZ LLC ）董事会工作，也是注册会计师协会的成员。他拥有商业学士学位和爱尔兰都柏林大学学院（University College in Dublin, Ireland）商业研究硕士学位。他在制药行业的财务专业知识和经验让他能够胜任董事会成员一职。
Conor M. Walshe has served on our Board of Directors since December 2014. Since January 2011 Mr. Walshe has held several positions at Perrigo Company plc, or Perrigo, including Vice President of Commercial Operations and Head of International Corporate Development. Prior to joining Perrigo, he held positions of Senior Director of Commercial Operations and Senior Director of Finance at Elan Pharmaceuticals, Inc., Head of Alltracel Healthcare Services Limited at Alltracel Pharmaceuticals plc and Director of Finance at ICON plc NASDAQ: ICLR and was an auditor at KPMG, Inc. He is also on the board of NewBridge Pharmaceuticals FZ LLC and a fellow of the Institute of Chartered Accountants. Mr. Walshe holds a Bachelor in Commerce and a Master’s in Business Studies from University College in Dublin, Ireland. - Conor M. Walshe ，2014年12月起在本董事会任职。在Perrigo担任几个职位，包括商务运营副总裁和独立公司发展负责人。在加入Perrigo之前，他担任Elan Pharmaceuticals股份有限公司（Elan Pharmaceuticals, Inc.）的商务运营的高级总监和财务高级总监；Alltracel Pharmaceuticals plc的 Alltracel Healthcare Services Limited负责人； ICON plc NASDAQ： ICLR的财务总监和KPMG股份有限公司（KPMG, Inc.）的审计师。他也在NewBridge Pharmaceuticals FZ 有限责任公司（NewBridge Pharmaceuticals FZ LLC ）董事会工作，也是注册会计师协会的成员。他拥有商业学士学位和爱尔兰都柏林大学学院（University College in Dublin, Ireland）商业研究硕士学位。他在制药行业的财务专业知识和经验让他能够胜任董事会成员一职。
- Conor M. Walshe has served on our Board of Directors since December 2014. Since January 2011 Mr. Walshe has held several positions at Perrigo Company plc, or Perrigo, including Vice President of Commercial Operations and Head of International Corporate Development. Prior to joining Perrigo, he held positions of Senior Director of Commercial Operations and Senior Director of Finance at Elan Pharmaceuticals, Inc., Head of Alltracel Healthcare Services Limited at Alltracel Pharmaceuticals plc and Director of Finance at ICON plc NASDAQ: ICLR and was an auditor at KPMG, Inc. He is also on the board of NewBridge Pharmaceuticals FZ LLC and a fellow of the Institute of Chartered Accountants. Mr. Walshe holds a Bachelor in Commerce and a Master’s in Business Studies from University College in Dublin, Ireland.
- Helen Boudreau
-
Helen Boudreau是一位退休的高级管理人员，在生物技术、制药、咨询和银行业拥有30年的经验。2018年至2019年，她担任非盈利生物技术公司比尔和梅琳达·盖茨医学研究所的首席运营官。此前，她曾担任公共和私营生物技术公司、Proteostasis Therapeutics（2017-2018年）和FORMA Therapeutics（2014-2017年）的首席财务官。海伦曾在诺华（2008-2014年）和辉瑞（1999-2008年）担任战略和高级财务职务，包括全球首席财务官、肿瘤业务部门首席财务官、美国企业首席财务官、投资者关系副总裁、财务副总裁、客户业务部门和商业运营副总裁，以及财务副总裁全球研发。海伦的职业生涯始于美国银行（1987-1991年），曾在麦肯锡公司担任项目经理（1993-1996年），并在百胜集团担任战略规划总监。品牌/百事可乐（1996-1999年）。海伦目前是医疗保健改善公司Premier, Inc.（纳斯达克股票代码：PINC）、专注于肿瘤学和自身免疫性疾病的生物技术公司Shattuck实验室（纳斯达克股票代码：STTK）和专注于罕见病的生物技术公司Rallybio（纳斯达克股票代码：RLYB）的董事会成员。海伦1987年以优异成绩获得马里兰大学经济学学士学位，1993年获得弗吉尼亚大学达顿商学院MBA学位。
Helen Boudreau,is a retired senior executive with 30 years experience across biotech, pharmaceuticals, consulting, and banking industries. She was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech, from 2018 to 2019. Previously, she served as CFO for public and private biotechs, Proteostasis Therapeutics (2017-2018) and FORMA Therapeutics (2014-2017). Helen worked at Novartis (2008-2014) and Pfizer (1999-2008), serving in strategy and senior finance roles, including global CFO Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. Helen started her career in banking at Bank of America (1987-1991), was an engagement manager at McKinsey & Company (1993-1996), and a Director of Strategic Planning at YUM! Brands/PepsiCo (1996-1999). Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, Shattuck Labs (NASDAQ:STTK), a biotech focused on oncology and autoimmune disease, and Rallybio, (NASDAQ:RLYB) a biotech company focused on rare diseases. Helen earned a BA in Economics, summa cum laude, from the University of Maryland in 1987, and an MBA from the Darden Graduate School of Business at the University of Virginia in 1993. - Helen Boudreau是一位退休的高级管理人员，在生物技术、制药、咨询和银行业拥有30年的经验。2018年至2019年，她担任非盈利生物技术公司比尔和梅琳达·盖茨医学研究所的首席运营官。此前，她曾担任公共和私营生物技术公司、Proteostasis Therapeutics（2017-2018年）和FORMA Therapeutics（2014-2017年）的首席财务官。海伦曾在诺华（2008-2014年）和辉瑞（1999-2008年）担任战略和高级财务职务，包括全球首席财务官、肿瘤业务部门首席财务官、美国企业首席财务官、投资者关系副总裁、财务副总裁、客户业务部门和商业运营副总裁，以及财务副总裁全球研发。海伦的职业生涯始于美国银行（1987-1991年），曾在麦肯锡公司担任项目经理（1993-1996年），并在百胜集团担任战略规划总监。品牌/百事可乐（1996-1999年）。海伦目前是医疗保健改善公司Premier, Inc.（纳斯达克股票代码：PINC）、专注于肿瘤学和自身免疫性疾病的生物技术公司Shattuck实验室（纳斯达克股票代码：STTK）和专注于罕见病的生物技术公司Rallybio（纳斯达克股票代码：RLYB）的董事会成员。海伦1987年以优异成绩获得马里兰大学经济学学士学位，1993年获得弗吉尼亚大学达顿商学院MBA学位。
- Helen Boudreau,is a retired senior executive with 30 years experience across biotech, pharmaceuticals, consulting, and banking industries. She was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech, from 2018 to 2019. Previously, she served as CFO for public and private biotechs, Proteostasis Therapeutics (2017-2018) and FORMA Therapeutics (2014-2017). Helen worked at Novartis (2008-2014) and Pfizer (1999-2008), serving in strategy and senior finance roles, including global CFO Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. Helen started her career in banking at Bank of America (1987-1991), was an engagement manager at McKinsey & Company (1993-1996), and a Director of Strategic Planning at YUM! Brands/PepsiCo (1996-1999). Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, Shattuck Labs (NASDAQ:STTK), a biotech focused on oncology and autoimmune disease, and Rallybio, (NASDAQ:RLYB) a biotech company focused on rare diseases. Helen earned a BA in Economics, summa cum laude, from the University of Maryland in 1987, and an MBA from the Darden Graduate School of Business at the University of Virginia in 1993.
- Franklin M. Berger
-
Franklin M. Berger，注册金融分析师。2004年6月起任公司董事。他已经通知董事会关于辞职一事，将于年度大会之后立即生效。他是生物科技行业分析师，拥有25余年资本市场和金融分析经验。他最近一职是在Sectoral Asset Management，2007至2008年6月任专注于低市值公司的基金NEMO Fund的创始人。此前，1998年5月至2003年3月，他在J.P. Morgan Securities担任股权研究管理合伙人以及高级生物科技分析师。在此岗位，他发起的团队覆盖26家生物科技公司，负责技术、科学和临床的尽职调查以及公司选择。1997年8月至1998年5月期间，他在Salomon Smith Barney担任相似职位；1991年11月至1997年8月期间，他在Josephthal & Co.也担任相似职位。他获有Harvard Graduate School of Business Administration的工商管理硕士学位，以及Johns Hopkins University的国际经济学硕士和国际关系学学士学位。除Seattle Genetics外，他还是上市生物科技公司BELLUS Health, Inc.和Five Prime Therapeutics, Inc.的董事。此外，他还曾担任VaxGen, Inc.、Isotechnika, Inc.、 Thallion Pharmaceuticals Inc.以及Emisphere Technologies, Inc.的董事，这些公司在他任职期间均为上市公司。
Franklin M. Berger has served as a member of our Board since January 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Prior to that, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Atreca Inc. since October 2014 Bellus Health, Inc. since May 2010 ESSA Pharma, Inc. since March 2015 and Atea Pharmaceuticals, Inc. since September 2019. Mr. Berger previously served as a member of the board of directors Five Prime Therapeutics, Inc., BioTime, Inc., Seattle Genetics, Inc., Proteostasis Therapeutics, Inc., Tocagen Inc. and Immune Design Corp., each publicly held biotechnology companies. Mr. Berger received a B.A. degree in international relations and a M.A. degree in international economics from Johns Hopkins University, and an M.B.A. degree from the Harvard Business School. - Franklin M. Berger，注册金融分析师。2004年6月起任公司董事。他已经通知董事会关于辞职一事，将于年度大会之后立即生效。他是生物科技行业分析师，拥有25余年资本市场和金融分析经验。他最近一职是在Sectoral Asset Management，2007至2008年6月任专注于低市值公司的基金NEMO Fund的创始人。此前，1998年5月至2003年3月，他在J.P. Morgan Securities担任股权研究管理合伙人以及高级生物科技分析师。在此岗位，他发起的团队覆盖26家生物科技公司，负责技术、科学和临床的尽职调查以及公司选择。1997年8月至1998年5月期间，他在Salomon Smith Barney担任相似职位；1991年11月至1997年8月期间，他在Josephthal & Co.也担任相似职位。他获有Harvard Graduate School of Business Administration的工商管理硕士学位，以及Johns Hopkins University的国际经济学硕士和国际关系学学士学位。除Seattle Genetics外，他还是上市生物科技公司BELLUS Health, Inc.和Five Prime Therapeutics, Inc.的董事。此外，他还曾担任VaxGen, Inc.、Isotechnika, Inc.、 Thallion Pharmaceuticals Inc.以及Emisphere Technologies, Inc.的董事，这些公司在他任职期间均为上市公司。
- Franklin M. Berger has served as a member of our Board since January 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Prior to that, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Atreca Inc. since October 2014 Bellus Health, Inc. since May 2010 ESSA Pharma, Inc. since March 2015 and Atea Pharmaceuticals, Inc. since September 2019. Mr. Berger previously served as a member of the board of directors Five Prime Therapeutics, Inc., BioTime, Inc., Seattle Genetics, Inc., Proteostasis Therapeutics, Inc., Tocagen Inc. and Immune Design Corp., each publicly held biotechnology companies. Mr. Berger received a B.A. degree in international relations and a M.A. degree in international economics from Johns Hopkins University, and an M.B.A. degree from the Harvard Business School.
- Christopher K. Mirabelli
-
Christopher K. Mirabelli，自2008年1月以来，是本公司的一位董事会成员。在担任Millennium Pharmaceuticals股份有限公司的医药研发总裁之前，曾于2000年加入HealthCare Ventures并担任总经理。在HealthCare Ventures的时候，他曾是Critical Therapeutics股份有限公司和其它各种私营公司担任高级职员和董事职位。1993-1999年期间，曾在一家生物技术公司- LeukoSite股份有限公司担任董事长和首席执行官。还曾是Isis Pharmaceuticals股份有限公司的一位联合创始人；此前曾在GSK的研发部门。他是哈佛医学院（Harvard Medical School）加速基金（Accelerator Fund）的一位顾问委员会成员；以及在遗传学顾问委员会任职。他还是SUNY-Fredonia国家科学咨询委员会的一位成员。他是从Baylor医学院获得他的分子药理学博士学位，以及从SUNY-Fredonia获得他的生物学学士学位的。
Christopher K. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000 Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. NASDAQ: IONS, where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia. - Christopher K. Mirabelli，自2008年1月以来，是本公司的一位董事会成员。在担任Millennium Pharmaceuticals股份有限公司的医药研发总裁之前，曾于2000年加入HealthCare Ventures并担任总经理。在HealthCare Ventures的时候，他曾是Critical Therapeutics股份有限公司和其它各种私营公司担任高级职员和董事职位。1993-1999年期间，曾在一家生物技术公司- LeukoSite股份有限公司担任董事长和首席执行官。还曾是Isis Pharmaceuticals股份有限公司的一位联合创始人；此前曾在GSK的研发部门。他是哈佛医学院（Harvard Medical School）加速基金（Accelerator Fund）的一位顾问委员会成员；以及在遗传学顾问委员会任职。他还是SUNY-Fredonia国家科学咨询委员会的一位成员。他是从Baylor医学院获得他的分子药理学博士学位，以及从SUNY-Fredonia获得他的生物学学士学位的。
- Christopher K. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000 Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. NASDAQ: IONS, where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
- M. James Barrett
-
M. James Barrett，自2003年起他一直是我们的董事会成员之一。目前，他担任 New Enterprise Associates（或者说 New，一个风险资本公司）的普通合伙人，在该公司他专注于生物技术，是其服务于医疗设备、医疗保健信息系统和医疗保健服务公司的医疗保健投资部门的成员。在加入 New 之前，自1997年至2001年，他创立了 Senseonics，一个医疗设备公司，并担任其主席和首席执行官。在那之前，他领导了3个由NEA提供资金的公司：自1987年至1995年，担任 Genetic Therapy, Inc.的主席和首席执行官；1982年至1987年，担任Life Technologies, Inc.及其前身， Bethesda Research Laboratories, Inc的总裁和首席执行官。之前，他任职于 SmithKline Beecham Corporation，在该公司担任过许多职务，包括其离体诊断部门的总裁和SmithKline临床实验室的总裁。目前，他任职于上市生命科学公司 Amicus Therapeutics, Inc., Clovis Oncology, Inc. 和 Supernus Pharmaceuticals, Inc.的董事会。在过去的5年里，他任职于上市公司Inhibitex, Inc.（被 Bristol-Myers Squibb Co.收购）、 YM Biosciences, Inc. 和 Targacept, Inc.。他取得了the University of Tennessee的生物化学哲学博士学位，以及 the University of Santa Clara 的工商管理学硕士学位，和Boston College。学士学位。
M. James Barrett has served as a member of our board of directors since our inception and serves as the chairman of our board of directors, and the chairman of our nominating and corporate governance committee. Since September 2001 he has served as a general partner of New Enterprise Associates Inc., a venture capital firm focusing on the healthcare, information technology and energy technology industries. From 1997 to 2001 Dr. Barrett served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, which he founded in 1997. Dr. Barrett serves on the boards of several pharmaceutical and biotechnology companies, including Galera Therapeutics, Inc., GlycoMimetics, Inc. NASDAQ: GLYC, PhaseBio Pharmaceuticals, Inc., Placon Therapeutics, Inc., Proteostasis Therapeutics, Inc. (NASDAQ: PTI), Psyadon Pharmaceuticals, Inc. (f/k/a Ruxton Pharmaceuticals, Inc.), Roka Bioscience, Inc. (NASDAQ: ROKA), Senseonics Holdings (NYSE: SENS) and Tarveda Therapeutics, Inc. (f/k/a Blend Biosciences, Inc.), as well as continuing to serve as Chairman of Sensors for Medicine and Science. Dr. Barrett previously served on the boards of, among others, Amicus Therapeutics, Inc. (NASDAQ: FOLD), Inhibitex, Inc. (NASDAQ: INHX) (acquired by Bristol-Myers Squibb (NASDAQ: BMY)), Loxo Oncology, Inc. (NASDAQ: LOXO), Pharmion Corporation (acquired in 2008), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), Targacept, Inc. (NASDAQ: TRGT), YM Biosciences, Inc. (AMEX: YMI) and Zosano Pharma Corporation (NASDAQ: ZSAN). Dr. Barrett received a Ph.D. in biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in chemistry from Boston College. - M. James Barrett，自2003年起他一直是我们的董事会成员之一。目前，他担任 New Enterprise Associates（或者说 New，一个风险资本公司）的普通合伙人，在该公司他专注于生物技术，是其服务于医疗设备、医疗保健信息系统和医疗保健服务公司的医疗保健投资部门的成员。在加入 New 之前，自1997年至2001年，他创立了 Senseonics，一个医疗设备公司，并担任其主席和首席执行官。在那之前，他领导了3个由NEA提供资金的公司：自1987年至1995年，担任 Genetic Therapy, Inc.的主席和首席执行官；1982年至1987年，担任Life Technologies, Inc.及其前身， Bethesda Research Laboratories, Inc的总裁和首席执行官。之前，他任职于 SmithKline Beecham Corporation，在该公司担任过许多职务，包括其离体诊断部门的总裁和SmithKline临床实验室的总裁。目前，他任职于上市生命科学公司 Amicus Therapeutics, Inc., Clovis Oncology, Inc. 和 Supernus Pharmaceuticals, Inc.的董事会。在过去的5年里，他任职于上市公司Inhibitex, Inc.（被 Bristol-Myers Squibb Co.收购）、 YM Biosciences, Inc. 和 Targacept, Inc.。他取得了the University of Tennessee的生物化学哲学博士学位，以及 the University of Santa Clara 的工商管理学硕士学位，和Boston College。学士学位。
- M. James Barrett has served as a member of our board of directors since our inception and serves as the chairman of our board of directors, and the chairman of our nominating and corporate governance committee. Since September 2001 he has served as a general partner of New Enterprise Associates Inc., a venture capital firm focusing on the healthcare, information technology and energy technology industries. From 1997 to 2001 Dr. Barrett served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, which he founded in 1997. Dr. Barrett serves on the boards of several pharmaceutical and biotechnology companies, including Galera Therapeutics, Inc., GlycoMimetics, Inc. NASDAQ: GLYC, PhaseBio Pharmaceuticals, Inc., Placon Therapeutics, Inc., Proteostasis Therapeutics, Inc. (NASDAQ: PTI), Psyadon Pharmaceuticals, Inc. (f/k/a Ruxton Pharmaceuticals, Inc.), Roka Bioscience, Inc. (NASDAQ: ROKA), Senseonics Holdings (NYSE: SENS) and Tarveda Therapeutics, Inc. (f/k/a Blend Biosciences, Inc.), as well as continuing to serve as Chairman of Sensors for Medicine and Science. Dr. Barrett previously served on the boards of, among others, Amicus Therapeutics, Inc. (NASDAQ: FOLD), Inhibitex, Inc. (NASDAQ: INHX) (acquired by Bristol-Myers Squibb (NASDAQ: BMY)), Loxo Oncology, Inc. (NASDAQ: LOXO), Pharmion Corporation (acquired in 2008), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), Targacept, Inc. (NASDAQ: TRGT), YM Biosciences, Inc. (AMEX: YMI) and Zosano Pharma Corporation (NASDAQ: ZSAN). Dr. Barrett received a Ph.D. in biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in chemistry from Boston College.
- Christopher T. Walsh
-
Christopher T. Walsh，2003年起，担任董事。1991年以来，他一直是Harvard Medical School生物化学与分子药理学的Hamilton Kuhn教授；曾担任Dana-Farber Cancer Institute的校长、Harvard Medical School生物化学与分子药理学系主席。他在酶立体化学、反应机制，以及抗感染和免疫抑制剂的作用机制等领域，从事过大量的研究工作。他目前是Abide Therapeutics、Epizyme Corporation、LS9 Inc、Health Care Ventures LLC Bioventures Group的科学顾问委员会成员。他还是Achaogen、Proteostasis Therapeutics的董事。他在Harvard University获生物学士学位，在纽约的The Rockefeller University获得生命科学博士学位。
Christopher T. Walsh has served as a director since 2003. Since October 2013 Dr. Walsh has been a consulting professor in Chemistry at Stanford University. Dr. Walsh was the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School from 1991 to July 2013 and formerly was president of the Dana-Farber Cancer Institute and chairman of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He has performed extensive research in enzyme stereochemistry, reaction mechanisms and the mechanisms of action of anti-infective and immunosuppressive agents. Dr. Walsh serves on the Scientific Advisory Board for Abide Therapeutics Inc., Hua Medicine Ltd., Leap Therapeutics, Inc., Cidara Therapeutics, Inc., the Bioventures Group of Health Care Ventures LLC and Flex Pharma, Inc. Dr. Walsh is also a board member of Proteostasis Therapeutics, Inc., and was a board member of Achaogen, Inc. from 2008 to 2016. He is also on the boards of directors of the nonprofit California Institute for Biomedical Research and the Scripps Research Institute. Dr. Walsh received an A.B. in biology from Harvard University and a Ph.D. in life sciences from The Rockefeller University, New York. - Christopher T. Walsh，2003年起，担任董事。1991年以来，他一直是Harvard Medical School生物化学与分子药理学的Hamilton Kuhn教授；曾担任Dana-Farber Cancer Institute的校长、Harvard Medical School生物化学与分子药理学系主席。他在酶立体化学、反应机制，以及抗感染和免疫抑制剂的作用机制等领域，从事过大量的研究工作。他目前是Abide Therapeutics、Epizyme Corporation、LS9 Inc、Health Care Ventures LLC Bioventures Group的科学顾问委员会成员。他还是Achaogen、Proteostasis Therapeutics的董事。他在Harvard University获生物学士学位，在纽约的The Rockefeller University获得生命科学博士学位。
- Christopher T. Walsh has served as a director since 2003. Since October 2013 Dr. Walsh has been a consulting professor in Chemistry at Stanford University. Dr. Walsh was the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School from 1991 to July 2013 and formerly was president of the Dana-Farber Cancer Institute and chairman of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He has performed extensive research in enzyme stereochemistry, reaction mechanisms and the mechanisms of action of anti-infective and immunosuppressive agents. Dr. Walsh serves on the Scientific Advisory Board for Abide Therapeutics Inc., Hua Medicine Ltd., Leap Therapeutics, Inc., Cidara Therapeutics, Inc., the Bioventures Group of Health Care Ventures LLC and Flex Pharma, Inc. Dr. Walsh is also a board member of Proteostasis Therapeutics, Inc., and was a board member of Achaogen, Inc. from 2008 to 2016. He is also on the boards of directors of the nonprofit California Institute for Biomedical Research and the Scripps Research Institute. Dr. Walsh received an A.B. in biology from Harvard University and a Ph.D. in life sciences from The Rockefeller University, New York.
高管简历
中英对照 | 中文 | 英文- Meenu Chhabra
Meenu Chhabra，自2014年5月起担任总裁、首席执行官和董事会成员。2007年8月-2014年5月她成为 Allozyne股份有限公司（ Allozyne, Inc.，一家生物制药公司）的总裁和首席执行官。2006年12月-2007年8月她担任Novartis AG NYSE： NVS。 的诺华（Novartis）制药部门的商务拓展和认证副总裁。2003年7月-2006年11月她在BioXell SpA（从F. Hoffmann-LaRoche Ltd.的米兰研究所（Milan Research Institute意大利（Italy））分离出来的公司）担任首席商务官，负责公司拓展和财务活动。Chhabra女士也在Fresenius Kabi AG、Warner-Lambert Company有限责任公司（Warner-Lambert Company, LLC）和Bristol-Myers Squibb公司（Bristol-Myers Squibb Company ,NYSE： BMY）担任管理职位。她获得约克大学（York University）工商管理硕士学位和多伦多大学（University of Toronto）学士学位。
Meenu Chhabra has been serving as our President and Chief Executive Officer and a member of our Board of Directors since May 2014. From August 2007 to May 2014 Ms. Chhabra was President and Chief Executive Officer at Allozyne, Inc., a biopharmaceutical company. From December 2006 to August 2007 she served as Vice President of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis AG NYSE: NVS. From July 2003 to November 2006 she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy), where she led corporate development and financing activities. Ms. Chhabra has also held management positions with Fresenius Kabi AG, Warner-Lambert Company, LLC, and Bristol-Myers Squibb Company (NYSE: BMY). She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto.- Meenu Chhabra，自2014年5月起担任总裁、首席执行官和董事会成员。2007年8月-2014年5月她成为 Allozyne股份有限公司（ Allozyne, Inc.，一家生物制药公司）的总裁和首席执行官。2006年12月-2007年8月她担任Novartis AG NYSE： NVS。 的诺华（Novartis）制药部门的商务拓展和认证副总裁。2003年7月-2006年11月她在BioXell SpA（从F. Hoffmann-LaRoche Ltd.的米兰研究所（Milan Research Institute意大利（Italy））分离出来的公司）担任首席商务官，负责公司拓展和财务活动。Chhabra女士也在Fresenius Kabi AG、Warner-Lambert Company有限责任公司（Warner-Lambert Company, LLC）和Bristol-Myers Squibb公司（Bristol-Myers Squibb Company ,NYSE： BMY）担任管理职位。她获得约克大学（York University）工商管理硕士学位和多伦多大学（University of Toronto）学士学位。
- Meenu Chhabra has been serving as our President and Chief Executive Officer and a member of our Board of Directors since May 2014. From August 2007 to May 2014 Ms. Chhabra was President and Chief Executive Officer at Allozyne, Inc., a biopharmaceutical company. From December 2006 to August 2007 she served as Vice President of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis AG NYSE: NVS. From July 2003 to November 2006 she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy), where she led corporate development and financing activities. Ms. Chhabra has also held management positions with Fresenius Kabi AG, Warner-Lambert Company, LLC, and Bristol-Myers Squibb Company (NYSE: BMY). She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto.
- Lance Thibault
Lance Thibault，自2015年4月起担任主要财务官兼临时首席财务官，并担任Danforth Advisors, LLC的一个顾问职位；2010年起担任独立顾问；目前是Paratek Pharmaceuticals, Inc.（纳斯达克： PRTK）的财务董事，并且为位于大波斯顿的多家私营制药公司提供运营、财务、战略支持服务。此前，他是deCODE genetics, Inc. （纳斯达克： DCGN）的首席财务官兼财务主管，在PricewaterhouseCoopers LLP担任过多个职位。他获得了Bentley University的会计学学士学位。
Lance Thibault has served as our Interim Chief Financial Officer since January 2022. Since January 2014 Mr. Thibault has served as managing director of Danforth Advisors, LLC providing operational, financial and strategic services at a number of private and public pharmaceutical and biotechnology companies, including as Interim Chief Financial Officer of Aadi Bioscience, Inc. NASDAQ: AADI from July 2021 to November 2021 as Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc (NASDAQ: PIRS) from February 2017 to April 2018 and as Interim Chief Financial Officer of Proteostasis Therapeutics, Inc. (NASDAQ: PTI) from April 2015 to August 2016. Prior to 2010 Mr. Thibault was Chief Financial Officer and Treasurer of deCODE genetics, Inc. (NASDAQ: DCGN), and a director at PricewaterhouseCoopers LLP. Mr. Thibault is a Certified Public Accountant and received his B.S. in Accountancy from Bentley University.- Lance Thibault，自2015年4月起担任主要财务官兼临时首席财务官，并担任Danforth Advisors, LLC的一个顾问职位；2010年起担任独立顾问；目前是Paratek Pharmaceuticals, Inc.（纳斯达克： PRTK）的财务董事，并且为位于大波斯顿的多家私营制药公司提供运营、财务、战略支持服务。此前，他是deCODE genetics, Inc. （纳斯达克： DCGN）的首席财务官兼财务主管，在PricewaterhouseCoopers LLP担任过多个职位。他获得了Bentley University的会计学学士学位。
- Lance Thibault has served as our Interim Chief Financial Officer since January 2022. Since January 2014 Mr. Thibault has served as managing director of Danforth Advisors, LLC providing operational, financial and strategic services at a number of private and public pharmaceutical and biotechnology companies, including as Interim Chief Financial Officer of Aadi Bioscience, Inc. NASDAQ: AADI from July 2021 to November 2021 as Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc (NASDAQ: PIRS) from February 2017 to April 2018 and as Interim Chief Financial Officer of Proteostasis Therapeutics, Inc. (NASDAQ: PTI) from April 2015 to August 2016. Prior to 2010 Mr. Thibault was Chief Financial Officer and Treasurer of deCODE genetics, Inc. (NASDAQ: DCGN), and a director at PricewaterhouseCoopers LLP. Mr. Thibault is a Certified Public Accountant and received his B.S. in Accountancy from Bentley University.
- Po Shun Lee
Po Shun Lee，自2015年12月起担任公司的执行副总裁，2015年6月起担任公司的医疗总监。2015年6月-2015年12月他也担任公司的临床开发高级副总裁；2014年11月-2015年6月担任临床开发副总裁。2013年2月-2014年11月他在诺华公司生物医学研究所（Novartis Institute for Biomedical Research）担任转化医学专家。2010年8月-2013年1月他担任Vertex Pharmaceuticals Incorporated NASDAQ： VRTX的医学部副主任，支持Kalydeco的临床开发和注册，并领导一个CFTR校正程序的概念证明。2005年6月-2010年8月他担任布里格姆妇女医院/哈佛医学院（Brigham and Women’s Hospital/Harvard Medical School）的医师科学家。他拥有宾夕法尼亚大学（ University of Pennsylvania ）硕士学位和约翰霍普金斯大学（Johns Hopkins University）生物学士学位。
Po Shun Lee has been serving as our Executive Vice President since December 2015 and our Chief Medical Officer since May 2015. He also served as our Senior Vice President, Clinical Development from May 2015 to December 2015 and as our Vice President, Clinical Development from November 2014 to May 2015. From February 2013 to November 2014 he served as Translational Medicine Expert at the Novartis Institute for Biomedical Research. From August 2010 to January 2013 Dr. Lee served as the Associate Medical Director at Vertex Pharmaceuticals Incorporated NASDAQ: VRTX where he supported the clinical development and registration of Kalydeco and led a CFTR corrector program to positive proof of concept. From May 2005 to August 2010 Dr. Lee served as a physician-scientist at the Brigham and Women’s Hospital/Harvard Medical School. He received an M.D. from the University of Pennsylvania and a B.A. in Biology from the Johns Hopkins University.- Po Shun Lee，自2015年12月起担任公司的执行副总裁，2015年6月起担任公司的医疗总监。2015年6月-2015年12月他也担任公司的临床开发高级副总裁；2014年11月-2015年6月担任临床开发副总裁。2013年2月-2014年11月他在诺华公司生物医学研究所（Novartis Institute for Biomedical Research）担任转化医学专家。2010年8月-2013年1月他担任Vertex Pharmaceuticals Incorporated NASDAQ： VRTX的医学部副主任，支持Kalydeco的临床开发和注册，并领导一个CFTR校正程序的概念证明。2005年6月-2010年8月他担任布里格姆妇女医院/哈佛医学院（Brigham and Women’s Hospital/Harvard Medical School）的医师科学家。他拥有宾夕法尼亚大学（ University of Pennsylvania ）硕士学位和约翰霍普金斯大学（Johns Hopkins University）生物学士学位。
- Po Shun Lee has been serving as our Executive Vice President since December 2015 and our Chief Medical Officer since May 2015. He also served as our Senior Vice President, Clinical Development from May 2015 to December 2015 and as our Vice President, Clinical Development from November 2014 to May 2015. From February 2013 to November 2014 he served as Translational Medicine Expert at the Novartis Institute for Biomedical Research. From August 2010 to January 2013 Dr. Lee served as the Associate Medical Director at Vertex Pharmaceuticals Incorporated NASDAQ: VRTX where he supported the clinical development and registration of Kalydeco and led a CFTR corrector program to positive proof of concept. From May 2005 to August 2010 Dr. Lee served as a physician-scientist at the Brigham and Women’s Hospital/Harvard Medical School. He received an M.D. from the University of Pennsylvania and a B.A. in Biology from the Johns Hopkins University.
- Benito Munoz
Benito Munoz， 自2015年12月起担任药物研发高级副总裁，2013年11月-2015年12月担任药物化学副总裁。2009年2月-2013年11月他担任博劳德研究所（Broad Institute，哈佛大学生物医学研究所）和麻省理工学院（Massachusetts Institute of Technology）的药物化学、分子库、探针和制作中心网络的董事。在他在博劳德研究所（Broad Institute）的职位中，Munoz博士负责设计和实施表型筛选平台去确定博劳德（Broad）收集的小分子中那些拥有治疗潜力，能对被忽视的疾病产生强有力的打击的积极分子。1999年10月-2008年10月他在Merck & Co. NYSE： MRK担任许多职位，承担着日益重要的责任，目前在美国马萨诸塞州波士顿（Boston, Massachusetts）的Merck & Co.实验室担任研究室主管；他先前在Karyopharm Therapeutics股份有限公司（Karyopharm Therapeutics, Inc. ，NASDAQ： KPTI）董事会任职。他拥有多伦多大学（University of Toronto）有机化学博士学位和布鲁克大学（Brock University）化学硕士学位。他也完成了斯克里普斯研究所（Scripps Research Institute）的博士后培训。
Benito Munoz has been serving as our Senior Vice President, Drug Discovery since December 2015 and served as our Vice President, Medicinal Chemistry from November 2013 to December 2015. From February 2009 to November 2013 he served as the Director of Medicinal Chemistry, Molecular Libraries Probe Productions Center Network, at the Broad Institute, a biomedical research institute affiliated with Harvard University and the Massachusetts Institute of Technology. In his role at the Broad Institute, Dr. Munoz was responsible for designing and implementing a phenotypic screening platform to identify active molecules within Broad’s collection of small molecules which generated potent hits with a therapeutic potential in neglected diseases. From October 1999 to October 2008 he served in a number of positions of increasing responsibility at Merck & Co. NYSE: MRK, most recently as a Director of Research Laboratories at Merck & Co.’s Boston, Massachusetts laboratories. He formerly served on the board of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Dr. Munoz received his Ph.D. in Organic Chemistry from the University of Toronto and an M.Sc. in Chemistry from Brock University. He also completed postdoctoral training at the Scripps Research Institute.- Benito Munoz， 自2015年12月起担任药物研发高级副总裁，2013年11月-2015年12月担任药物化学副总裁。2009年2月-2013年11月他担任博劳德研究所（Broad Institute，哈佛大学生物医学研究所）和麻省理工学院（Massachusetts Institute of Technology）的药物化学、分子库、探针和制作中心网络的董事。在他在博劳德研究所（Broad Institute）的职位中，Munoz博士负责设计和实施表型筛选平台去确定博劳德（Broad）收集的小分子中那些拥有治疗潜力，能对被忽视的疾病产生强有力的打击的积极分子。1999年10月-2008年10月他在Merck & Co. NYSE： MRK担任许多职位，承担着日益重要的责任，目前在美国马萨诸塞州波士顿（Boston, Massachusetts）的Merck & Co.实验室担任研究室主管；他先前在Karyopharm Therapeutics股份有限公司（Karyopharm Therapeutics, Inc. ，NASDAQ： KPTI）董事会任职。他拥有多伦多大学（University of Toronto）有机化学博士学位和布鲁克大学（Brock University）化学硕士学位。他也完成了斯克里普斯研究所（Scripps Research Institute）的博士后培训。
- Benito Munoz has been serving as our Senior Vice President, Drug Discovery since December 2015 and served as our Vice President, Medicinal Chemistry from November 2013 to December 2015. From February 2009 to November 2013 he served as the Director of Medicinal Chemistry, Molecular Libraries Probe Productions Center Network, at the Broad Institute, a biomedical research institute affiliated with Harvard University and the Massachusetts Institute of Technology. In his role at the Broad Institute, Dr. Munoz was responsible for designing and implementing a phenotypic screening platform to identify active molecules within Broad’s collection of small molecules which generated potent hits with a therapeutic potential in neglected diseases. From October 1999 to October 2008 he served in a number of positions of increasing responsibility at Merck & Co. NYSE: MRK, most recently as a Director of Research Laboratories at Merck & Co.’s Boston, Massachusetts laboratories. He formerly served on the board of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Dr. Munoz received his Ph.D. in Organic Chemistry from the University of Toronto and an M.Sc. in Chemistry from Brock University. He also completed postdoctoral training at the Scripps Research Institute.
- Janet L. Smart
Janet L. Smart，自2014年1月起担任知识产权及法律事务副总裁；2011年9月至2014年1月间担任知识资产高级主管；2010年8月至2011年10月间担任Anchor Therapeutics, Inc.（生物技术公司）的法律事务高级主管，负责知识产权和企业事务。她是一名专利律师，在the U.S. Patent and Trademark Office注册执业。她获得了Franklin Pierce Law Center（现为University of New Hampshire School of Law）的法学博士学位，以及Northeastern University的学士、硕士、博士学位。
Janet L. Smart has been serving as our Vice President, Intellectual Property and Legal Affairs since January 2014 and served as our Senior Director, Intellectual Assets from September 2011 to January 2014. From August 2010 to October 2011 Dr. Smart was Senior Director of Legal Affairs at Anchor Therapeutics, Inc., a biotechnology company, where she was responsible for intellectual property and corporate matters. Dr. Smart is a Patent Attorney registered to practice before the U.S. Patent and Trademark Office. She received a J.D. from Franklin Pierce Law Center now University of New Hampshire School of Law and B.S., M.S. and Ph.D. degrees from Northeastern University.- Janet L. Smart，自2014年1月起担任知识产权及法律事务副总裁；2011年9月至2014年1月间担任知识资产高级主管；2010年8月至2011年10月间担任Anchor Therapeutics, Inc.（生物技术公司）的法律事务高级主管，负责知识产权和企业事务。她是一名专利律师，在the U.S. Patent and Trademark Office注册执业。她获得了Franklin Pierce Law Center（现为University of New Hampshire School of Law）的法学博士学位，以及Northeastern University的学士、硕士、博士学位。
- Janet L. Smart has been serving as our Vice President, Intellectual Property and Legal Affairs since January 2014 and served as our Senior Director, Intellectual Assets from September 2011 to January 2014. From August 2010 to October 2011 Dr. Smart was Senior Director of Legal Affairs at Anchor Therapeutics, Inc., a biotechnology company, where she was responsible for intellectual property and corporate matters. Dr. Smart is a Patent Attorney registered to practice before the U.S. Patent and Trademark Office. She received a J.D. from Franklin Pierce Law Center now University of New Hampshire School of Law and B.S., M.S. and Ph.D. degrees from Northeastern University.